Fluocinonide
 Fluocinonide Cream

drug-information.ru

|Fluocinonide Fluocinonide Cream

Drugs search, click the first letter of a drug name:


| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9  Home

Fluocinonide

Dosage Form: Cream, gel, ointment usp

Fluocinonide Description

The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. The topical corticosteroids are intended for topical administration. The active component is the corticosteroid Fluocinonide, which is the 21-acetate ester of fluocinolone acetonide and has the chemical name pregna-1,4-diene-3,20-dione,21-(acetyloxy)-6,9-difluoro-11-hydroxy-16,17-[(1-methylethylidene) bis(oxy)]-,(6α, 11β, 16α)-. It has the following structural formula:

C26H32F207 M.W. 494.54

Each gram of Fluocinonide Cream USP, 0.05% (Emulsified Base) contains: 0.5 mg Fluocinonide in a water-washable aqueous emollient base of stearyl alcohol, cetyl alcohol, mineral oil, propylene glycol, sorbitan monostearate, polysorbate 60, citric acid (hydrous) and purified water.

Each gram of Fluocinonide Cream USP, 0.05% contains: 0.5 mg Fluocinonide in a specially formulated cream base consisting of stearyl alcohol, polyethylene glycol 8000, propylene glycol, 1,2,6-hexanetriol and citric acid (hydrous). This white cream vehicle is greaseless, non-staining, anhydrous and completely water miscible. The base provides emollient and hydrophilic properties.

In this formulation, the active ingredient is totally in solution.

Each gram of Fluocinonide Gel USP, 0.05% contains: 0.5 mg Fluocinonide in a specifically formulated gel base consisting of purified water, propylene glycol, edetate disodium, carbomer 934P, and sodium hydroxide. Hydrochloric acid is added to adjust the pH. This clear, colorless thixotropic vehicle is greaseless, non-staining and completely water miscible.

In this formulation, the active ingredient is totally in solution.

Each gram of Fluocinonide Ointment USP, 0.05% contains: 0.5 mg Fluocinonide in an ointment base consisting of white petrolatum, castor oil, and sorbitan sesquioleate. It provides the occlusive and emollient effects desirable in an ointment.

In this formulation, the active ingredient is totally in solution.

Fluocinonide - Clinical Pharmacology

Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions.

The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.

Pharmacokinetics

The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.

Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses. (See DOSAGE AND ADMINISTRATION).

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

Indications and Usage for Fluocinonide

The topical corticosteriods are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Contraindications

The topical corticosteriods are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Precautions

General

Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing"s syndrome, hyperglycemia, and glucosuria in some patients.

Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.

Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.

Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.

Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. (See PRECAUTIONS - Pediatric Use). If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.

As with any topical corticosteroid product, prolonged use may produce atrophy of the skin and subcutaneous tissues. When used on intertriginous or flexor areas, or on the face, this may occur even with short-term use.

In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

Information for Patients

Patients using topical corticosteroids should receive the following information and instructions:

  1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
  2. Patients should be advised not to use this medication for any disorder other than that for which it was prescribed.
  3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.
  4. Patients should report any signs of local adverse reactions especially under occlusive dressing.
  5. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.

Laboratory Tests

The following tests may be helpful in evaluating the HPA axis suppression:

Urinary free cortisol test

ACTH stimulation test

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids.

Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.

Pregnancy

Teratogenic Effects

Pregnancy Category C

Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

Nursing Mothers

It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

Pediatric Use

Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing"s syndrome than mature patients because of a larger skin surface area to body weight ratio.

Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing"s syndrome, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

Administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of pediatric patients.

Adverse Reactions

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence:

Burning Perioral dermatitis
Itching Allergic contact dermatitis
Irritation Maceration of the skin
Dryness Secondary infection
Folliculitis Skin atrophy
Hypertrichosis Striae
Acneiform eruptions Miliaria
Hypopigmentation

Overdosage

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. (See PRECAUTIONS).

Fluocinonide Dosage and Administration

The topical corticosteroids are generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition.

Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions.

If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

How is Fluocinonide Supplied

Fluocinonide Cream USP, 0.05% (Emulsified Base) is supplied in 15 gram, 30 gram, and 60 gram tubes.

Fluocinonide Cream USP, 0.05% is supplied in 15 gram, 30 gram, and 60 gram tubes.

Fluocinonide Gel USP, 0.05% is supplied in 60 gram tubes.

Fluocinonide Ointment USP, 0.05% is supplied in 15 gram, 30 gram, and 60 gram tubes.

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

Avoid excessive heat, above 40°C (104°F).

Rev. K 3/2005

Manufactured By:

TEVA PHARMACEUTICALS USA

Sellersville, PA 18960


Fluocinonide (Fluocinonide)
PRODUCT INFO
Product Code 0093-0263 Dosage Form CREAM
Route Of Administration TOPICAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
Fluocinonide (Fluocinonide) Active 0.5 MILLIGRAM  In 1 GRAM
stearyl alcohol Inactive  
cetyl alcohol Inactive  
mineral oil Inactive  
propylene glycol Inactive  
sorbitan monostearate Inactive  
polysorbate 60 Inactive  
citric acid (hydrous) Inactive  
water Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color Score
Shape Symbol
Imprint Code Coating
Size
PACKAGING
# NDC Package Description Multilevel Packaging
1 0093-0263-15 15 GRAM In 1 TUBE None
2 0093-0263-30 30 GRAM In 1 TUBE None
3 0093-0263-92 60 GRAM In 1 TUBE None

Fluocinonide (Fluocinonide)
PRODUCT INFO
Product Code 0093-0262 Dosage Form CREAM
Route Of Administration TOPICAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
Fluocinonide (Fluocinonide) Active 0.5 MILLIGRAM  In 1 GRAM
stearyl alcohol Inactive  
polyethylene glycol 8000 Inactive  
propylene glycol Inactive  
1,2,6-hexanetriol Inactive  
citric acid (hydrous) Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color Score
Shape Symbol
Imprint Code Coating
Size
PACKAGING
# NDC Package Description Multilevel Packaging
1 0093-0262-15 15 GRAM In 1 TUBE None
2 0093-0262-30 30 GRAM In 1 TUBE None
3 0093-0262-92 60 GRAM In 1 TUBE None

Fluocinonide (Fluocinonide)
PRODUCT INFO
Product Code 0093-0265 Dosage Form GEL
Route Of Administration TOPICAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
Fluocinonide (Fluocinonide) Active 0.5 MILLIGRAM  In 1 GRAM
water Inactive  
propylene glycol Inactive  
edetate disodium Inactive  
carbomer 934P Inactive  
sodium hydroxide Inactive  
hydrochloric acid Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color Score
Shape Symbol
Imprint Code Coating
Size
PACKAGING
# NDC Package Description Multilevel Packaging
1 0093-0265-92 60 GRAM In 1 TUBE None

Fluocinonide (Fluocinonide)
PRODUCT INFO
Product Code 0093-0264 Dosage Form OINTMENT
Route Of Administration TOPICAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
Fluocinonide (Fluocinonide) Active 0.5 MILLIGRAM  In 1 GRAM
white petrolatum Inactive  
castor oil Inactive  
sorbitan sesquioleate Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color Score
Shape Symbol
Imprint Code Coating
Size
PACKAGING
# NDC Package Description Multilevel Packaging
1 0093-0264-15 15 GRAM In 1 TUBE None
2 0093-0264-30 30 GRAM In 1 TUBE None
3 0093-0264-92 60 GRAM In 1 TUBE None

Revised: 09/2006





Where can I get more information about Fluocinonide Fluocinonide Cream ? We recommend to use www.Drugs.com

Typical mistypes for Fluocinonide Fluocinonide Cream
dluocinonide fluocinonide cream, cluocinonide fluocinonide cream, vluocinonide fluocinonide cream, gluocinonide fluocinonide cream, tluocinonide fluocinonide cream, rluocinonide fluocinonide cream, fkuocinonide fluocinonide cream, fpuocinonide fluocinonide cream, fouocinonide fluocinonide cream, flyocinonide fluocinonide cream, flhocinonide fluocinonide cream, fljocinonide fluocinonide cream, fliocinonide fluocinonide cream, fl8ocinonide fluocinonide cream, fl7ocinonide fluocinonide cream, fluicinonide fluocinonide cream, flukcinonide fluocinonide cream, flulcinonide fluocinonide cream, flupcinonide fluocinonide cream, flu0cinonide fluocinonide cream, flu9cinonide fluocinonide cream, fluoxinonide fluocinonide cream, fluovinonide fluocinonide cream, fluofinonide fluocinonide cream, fluodinonide fluocinonide cream, fluocunonide fluocinonide cream, fluocjnonide fluocinonide cream, fluocknonide fluocinonide cream, fluocononide fluocinonide cream, fluoc9nonide fluocinonide cream, fluoc8nonide fluocinonide cream, fluocibonide fluocinonide cream, fluocimonide fluocinonide cream, fluocijonide fluocinonide cream, fluocihonide fluocinonide cream, fluocininide fluocinonide cream, fluocinknide fluocinonide cream, fluocinlnide fluocinonide cream, fluocinpnide fluocinonide cream, fluocin0nide fluocinonide cream, fluocin9nide fluocinonide cream, fluocinobide fluocinonide cream, fluocinomide fluocinonide cream, fluocinojide fluocinonide cream, fluocinohide fluocinonide cream, fluocinonude fluocinonide cream, fluocinonjde fluocinonide cream, fluocinonkde fluocinonide cream, fluocinonode fluocinonide cream, fluocinon9de fluocinonide cream, fluocinon8de fluocinonide cream, fluocinonise fluocinonide cream, fluocinonixe fluocinonide cream, fluocinonice fluocinonide cream, fluocinonife fluocinonide cream, fluocinonire fluocinonide cream, fluocinoniee fluocinonide cream, fluocinonidw fluocinonide cream, fluocinonids fluocinonide cream, fluocinonidd fluocinonide cream, fluocinonidr fluocinonide cream, fluocinonid4 fluocinonide cream, fluocinonid3 fluocinonide cream, fluocinonide dluocinonide cream, fluocinonide cluocinonide cream, fluocinonide vluocinonide cream, fluocinonide gluocinonide cream, fluocinonide tluocinonide cream, fluocinonide rluocinonide cream, fluocinonide fkuocinonide cream, fluocinonide fpuocinonide cream, fluocinonide fouocinonide cream, fluocinonide flyocinonide cream, fluocinonide flhocinonide cream, fluocinonide fljocinonide cream, fluocinonide fliocinonide cream, fluocinonide fl8ocinonide cream, fluocinonide fl7ocinonide cream, fluocinonide fluicinonide cream, fluocinonide flukcinonide cream, fluocinonide flulcinonide cream, fluocinonide flupcinonide cream, fluocinonide flu0cinonide cream, fluocinonide flu9cinonide cream, fluocinonide fluoxinonide cream, fluocinonide fluovinonide cream, fluocinonide fluofinonide cream, fluocinonide fluodinonide cream, fluocinonide fluocunonide cream, fluocinonide fluocjnonide cream, fluocinonide fluocknonide cream, fluocinonide fluocononide cream, fluocinonide fluoc9nonide cream, fluocinonide fluoc8nonide cream, fluocinonide fluocibonide cream, fluocinonide fluocimonide cream, fluocinonide fluocijonide cream, fluocinonide fluocihonide cream, fluocinonide fluocininide cream, fluocinonide fluocinknide cream, fluocinonide fluocinlnide cream, fluocinonide fluocinpnide cream, fluocinonide fluocin0nide cream, fluocinonide fluocin9nide cream, fluocinonide fluocinobide cream, fluocinonide fluocinomide cream, fluocinonide fluocinojide cream, fluocinonide fluocinohide cream, fluocinonide fluocinonude cream, fluocinonide fluocinonjde cream, fluocinonide fluocinonkde cream, fluocinonide fluocinonode cream, fluocinonide fluocinon9de cream, fluocinonide fluocinon8de cream, fluocinonide fluocinonise cream, fluocinonide fluocinonixe cream, fluocinonide fluocinonice cream, fluocinonide fluocinonife cream, fluocinonide fluocinonire cream, fluocinonide fluocinoniee cream, fluocinonide fluocinonidw cream, fluocinonide fluocinonids cream, fluocinonide fluocinonidd cream, fluocinonide fluocinonidr cream, fluocinonide fluocinonid4 cream, fluocinonide fluocinonid3 cream, fluocinonide fluocinonide xream, fluocinonide fluocinonide vream, fluocinonide fluocinonide fream, fluocinonide fluocinonide dream, fluocinonide fluocinonide ceeam, fluocinonide fluocinonide cdeam, fluocinonide fluocinonide cfeam, fluocinonide fluocinonide cteam, fluocinonide fluocinonide c5eam, fluocinonide fluocinonide c4eam, fluocinonide fluocinonide crwam, fluocinonide fluocinonide crsam, fluocinonide fluocinonide crdam, fluocinonide fluocinonide crram, fluocinonide fluocinonide cr4am, fluocinonide fluocinonide cr3am, fluocinonide fluocinonide crezm, fluocinonide fluocinonide cresm, fluocinonide fluocinonide crewm, fluocinonide fluocinonide creqm, fluocinonide fluocinonide crean, fluocinonide fluocinonide creak, fluocinonide fluocinonide creaj, luocinonide fluocinonide cream, fuocinonide fluocinonide cream, flocinonide fluocinonide cream, flucinonide fluocinonide cream, fluoinonide fluocinonide cream, fluocnonide fluocinonide cream, fluocionide fluocinonide cream, fluocinnide fluocinonide cream, fluocinoide fluocinonide cream, fluocinonde fluocinonide cream, fluocinonie fluocinonide cream, fluocinonid fluocinonide cream, fluocinonide fluocinonide cream, fluocinonide fluocinonide cream, fluocinonide luocinonide cream, fluocinonide fuocinonide cream, fluocinonide flocinonide cream, fluocinonide flucinonide cream, fluocinonide fluoinonide cream, fluocinonide fluocnonide cream, fluocinonide fluocionide cream, fluocinonide fluocinnide cream, fluocinonide fluocinoide cream, fluocinonide fluocinonde cream, fluocinonide fluocinonie cream, fluocinonide fluocinonid cream, fluocinonide fluocinonidecream, fluocinonide fluocinonide ream, fluocinonide fluocinonide ceam, fluocinonide fluocinonide cram, fluocinonide fluocinonide crem, fluocinonide fluocinonide crea, lfuocinonide fluocinonide cream, fulocinonide fluocinonide cream, floucinonide fluocinonide cream, flucoinonide fluocinonide cream, fluoicnonide fluocinonide cream, fluocnionide fluocinonide cream, fluocionnide fluocinonide cream, fluocinnoide fluocinonide cream, fluocinoinde fluocinonide cream, fluocinondie fluocinonide cream, fluocinonied fluocinonide cream, fluocinonid e fluocinonide cream, fluocinonide fluocinonide cream, fluocinonide f luocinonide cream, fluocinonide lfuocinonide cream, fluocinonide fulocinonide cream, fluocinonide floucinonide cream, fluocinonide flucoinonide cream, fluocinonide fluoicnonide cream, fluocinonide fluocnionide cream, fluocinonide fluocionnide cream, fluocinonide fluocinnoide cream, fluocinonide fluocinoinde cream, fluocinonide fluocinondie cream, fluocinonide fluocinonied cream, fluocinonide fluocinonid ecream, fluocinonide fluocinonidec ream, fluocinonide fluocinonide rceam, fluocinonide fluocinonide ceram, fluocinonide fluocinonide craem, fluocinonide fluocinonide crema, ffluocinonide fluocinonide cream, flluocinonide fluocinonide cream, fluuocinonide fluocinonide cream, fluoocinonide fluocinonide cream, fluoccinonide fluocinonide cream, fluociinonide fluocinonide cream, fluocinnonide fluocinonide cream, fluocinoonide fluocinonide cream, fluocinonnide fluocinonide cream, fluocinoniide fluocinonide cream, fluocinonidde fluocinonide cream, fluocinonidee fluocinonide cream, fluocinonide fluocinonide cream, fluocinonide fluocinonide cream, fluocinonide ffluocinonide cream, fluocinonide flluocinonide cream, fluocinonide fluuocinonide cream, fluocinonide fluoocinonide cream, fluocinonide fluoccinonide cream, fluocinonide fluociinonide cream, fluocinonide fluocinnonide cream, fluocinonide fluocinoonide cream, fluocinonide fluocinonnide cream, fluocinonide fluocinoniide cream, fluocinonide fluocinonidde cream, fluocinonide fluocinonidee cream, fluocinonide fluocinonide cream, fluocinonide fluocinonide ccream, fluocinonide fluocinonide crream, fluocinonide fluocinonide creeam, fluocinonide fluocinonide creaam, fluocinonide fluocinonide creamm, etc.



© Copyright by drug-information.ru 2001-2019. All rights reserved